PRFX News and Press, PainReform Ltd. From 04/20/21

PainReform Ltd. (NASDAQ:PRFX) traded at a new 52-week low today of $3.16. So far today approximately 500,000 shares have been exchanged, as compared to an average 30-day volume of 136,000 shares. PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the re...

Shares of PainReform Ltd. (NASDAQ:PRFX) traded today at $3.09, breaking its 52-week low. Approximately 500,000 shares have changed hands today, as compared to an average 30-day volume of 136,000 shares. Potential upside of 40.2% exists for PainReform Ltd., based on a current level of $3....

PainReform Ltd. (NASDAQ:PRFX) traded at a new 52-week low today of $3.70. This new low was reached on above average trading volume as 500,000 shares traded hands, while the average 30-day volume is approximately 136,000 shares. PainReform Ltd. has overhead space with shares priced $3.89,...

Shares of PainReform Ltd. (NASDAQ:PRFX) traded today at $3.61, breaking its 52-week low. This new low was reached on above average trading volume as 500,000 shares traded hands, while the average 30-day volume is approximately 136,000 shares. In the past 52 weeks, shares of PainReform Lt...

Gainers: Clovis Oncology (CLVS) +43%, Marker Therapeutics (MRKR) +23%, Alector (ALEC) +17%, Aravive (ARAV) +14%, Ortho Clinical Diagnostics (OCDX) +8%.Losers: Idera Pharmaceuticals (IDRA) -62%, Praxis Precision Medicines (PRAX) -13%,  Acu...

HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end busi...

PainReform ([[PRFX]] +3.6%) entered into securities purchase agreements with certain institutional investors to raise ~$6M  through the private placement of 1.3M shares and accompanying warrants to purchase 652,173 shares at a combined purchase price of $4.60/share and accompanying ...

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered in...

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be present...

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita...